ClinicalTrials.gg

Program

olverembatinib

Also written as “HQP1351”, “Olverembatinib” and “Olverembatinib 20mg”.

Its studies are mostly in Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Leukemia, Myeloid, Chronic-Phase · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Gastrointestinal Stromal Tumors · Leukemia, Myeloid, Accelerated Phase, led by Ascentage Pharma Group International.

Furthest: phase 3, since Sep 4, 202310 company-led studies, 5 open or runningNext primary completion: Mar 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ascentage Pharma Group International105 open or runningphase 3since Sep 4, 2023Jul 1, 2018Mar 31, 2027phase 3 · NCT06640361

Also a collaborator on its studies: HealthQuest Pharma.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 1, 2018First study: phase 1 study in Gastrointestinal Stromal TumorsFirst studyNCT03594422 · 100 planned · China
  2. Mar 12, 2019Phase 1 study in Leukemia, Myeloid, Chronic-PhaseNCT03882281 · 12 enrolled · China
  3. Mar 13, 20192 phase 2 studiesNCT03883100, NCT03883087
  4. Sep 18, 2019Phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04260022 · 242 planned · United States, Canada
  5. Oct 11, 2019Phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04126707 · 6 enrolled · China
  6. Oct 11, 2019Phase 2 study in Leukemia, Myeloid, Chronic-PhaseNCT04126681 · 144 enrolled · China
  7. Sep 4, 2023Phase 3 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNCT06051409 · 350 planned · United States, Australia, China and more
  8. Oct 11, 2024Phase 3 study in GISTNCT06640361 · 40 planned · China
  9. Nov 19, 2025Phase 1 study in PharmacokineticNCT07282093 · 48 planned · China

Ahead

  1. Mar 31, 2027Primary completion: phase 3 study in GISTNCT06640361
  2. Dec 2027Primary completion: phase 1 study in Gastrointestinal Stromal TumorsNCT03594422
  3. Dec 31, 2027Primary completion: phase 3 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNCT06051409
  4. Dec 27, 2029Primary completion: phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04260022

TargetBeta

“An orally bioavailable inhibitor of a variety of kinases, including the Bcr-Abl tyrosine kinase, the mast/stem cell growth factor receptor Kit (c-Kit), the serine/threonine protein kinase Akt (protein kinase B), and the extracellular signal-regulated kinase (ERK) with antineoplastic activity”NCIt, by rule
“Bcr/Abl fusion protein inhibitor”ChEMBL 37, by rule

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07282093Pharmacokinetic · China1RecruitingJun 30, 202648
NCT06640361GIST · China3RecruitingMar 31, 202740
NCT06051409Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States, Australia, China and more3RecruitingDec 31, 2027350
NCT04126707Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China1CompletedJan 13, 20206
NCT04126681Leukemia, Myeloid, Chronic-Phase · China2CompletedAug 1, 2024144
NCT04260022Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Canada1RecruitingDec 27, 2029242
NCT03883100Leukemia, Myeloid, Accelerated Phase · China2UNKNOWNApr 202423
NCT03883087Leukemia, Myeloid, Chronic-Phase · China2UNKNOWNMay 202441
NCT03882281Leukemia, Myeloid, Chronic-Phase · China1CompletedNov 16, 201912
NCT03594422Gastrointestinal Stromal Tumors · China1RecruitingDec 2027100

How it is read

Names in the registry

  • “HQP1351”, 5 entries
  • “Olverembatinib”, 2 entries
  • “Olverembatinib 20mg”, 1 entry
  • “Ascentage Pharma HQP1351 bioavailable inhibitor”, 1 entry
  • “[14C] HQP1351”, 1 entry

Codes read as this program: HQP1351.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.